TAK R&D to Revenue
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) · R&D to Revenue
TAK R&D to Revenue
Latest reported13.72%period ending
TAK Quarterly R&D/Revenue (21.02% → 13.72%)
Latest values, visible window
High-resolution chart · PNG
TAK r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 13.722% | |
| 17.8449% | |
| 14.7043% | |
| 14.5114% | |
| 13.002% | |
| 20.5057% | |
| 14.8754% | |
| 14.9284% | |
| 13.9457% | |
| 18.6375% | |
| 16.8632% | |
| 17.6347% | |
| 15.373% | |
| 16.8324% | |
| 15.9253% | |
| 15.379% | |
| 14.7673% | |
| 16.4468% | |
| 14.2437% | |
| 15.5773% | |
| 12.898% | |
| 14.7076% | |
| 14.0503% | |
| 14.9768% | |
| 13.3218% | |
| 17.3642% | |
| 14.2798% | |
| 13.9939% | |
| 13.7632% | |
| 19.4371% | |
| 15.5108% | |
| 18.4471% | |
| 15.9983% | |
| 22.1422% | |
| 16.7088% | |
| 18.3315% | |
| 16.8856% | |
| 21.2645% | |
| 15.4465% | |
| 18.0943% | |
| 17.638% | |
| 22.2227% | |
| 18.9132% | |
| 17.5601% | |
| 18.1474% | |
| 30.3465% | |
| 18.9729% | |
| 18.483% | |
| 18.2793% | |
| 25.5344% | |
| 18.1127% | |
| 18.3466% | |
| 18.8997% | |
| 25.1843% | |
| 19.1204% | |
| 19.5035% | |
| 19.8041% | |
| 0% | |
| 16.6398% | |
| 17.7495% | |
| 16.1568% | |
| 0% | |
| 17.9257% | |
| 17.2773% | |
| 17.5115% | |
| 0% | |
| 19.7851% | |
| 18.7831% | |
| 17.1163% | |
| 0% | |
| 14.2892% | |
| 21.0201% |